The market share for Zubsolv (4w rolling average) reached 5.2% in prescriptions and 5.6% in quantity in May, according to latest data from Symphony Health Solutions, released today. The data indicates a continued strong underlying demand for buprenorphine/naloxone drugs in the US, with a y/y growth rate of 12.0% (quantity) and of 11.7% (prescriptions) in May. With a growing underlying market and a somewhat improved market share in May (compared to last year), this translates into a y/y increase of Zubsolv prescriptions and tablets of 10.4% and 16.7% respectively.